[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcopenia-in-liver-cirrhosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcopenia-in-liver-cirrhosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100615325","a-comparative-study-of-mri-and-ultrasound-for-detection-of-primary-hepatocellular-carcinoma-body-composition-and-risk-factors-for-decompensation-in-liver-cirrhosis-100615325",false,"NCT07291141","A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis","DETECT-HCC","Inclusion Criteria:\n\n* Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.\n* Age ≥18 years ≤ 84\n* Written informed consent from the participant\n\nExclusion Criteria:\n\n* Contraindications for MRI (ferrrous material, claustrophobia)\n* Pregnancy\n* Diagnosis of primary sclerosing cholangitis (PSC)\n* Vascular liver disease\n* Congenital liver fibrosis\n* Previous diagnosis of hepatic carcinoma (HCC)\n* Previous liver transplant","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.\n\nA key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.\n\nThe protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.\n\nLongitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.\n\nThe DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.",[24,25,26,27,28,29],"Liver Cirrhoses","Hepatocellular Carcinoma (HCC)","Sarcopenia in Liver Cirrhosis","Portal Hypertension Related to Cirrhosis","MRI","Ultrasound",[31,32,33,34],"Abbreviated MRI","Hepatocellular carcinoma","Liver cirrhosis","Sarcopenia","RECRUITING","2025-12-18",{"date":38,"type":39},"2025-12-19","ACTUAL",{"date":36,"type":39},{"date":42,"type":20},"2031-12",{"name":44,"class":45},"Mattias Ekstedt","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":5},"100578694","phase-3-role-of-nutritional-intervention-for-the-treatment-of-sarcopenia-in-cirrhotic-patients-with-refractory-ascites-candidate-to-transjugular-intrahepatic-portosystemic-shunt-placement-and-identification-of-prognostic-factors-related-to-clinical-outcome-100578694","NCT06814626","Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome","Role of Nutritional Intervention with Friliver for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome","NS-TIPS","Inclusion Criteria:\n\n* men and women with an age ≥ 18 and ≤ 80 years\n* clinical, radiological or histological diagnosis of liver cirrhosis\n* diagnosis of RA\n* confirmation of sarcopenia defined in CT scan as the sum of the psoas muscle areas measured at the level of the 3rd lumbar vertebra (PMA) ≤16 cm2\n* informed consent signed\n\nExclusion Criteria:\n\n* severe hepatic insufficiency (bilirubin\\> 5 mg\u002Fdl, MELD score\\> 18, Child-Pugh score\\> 9)\n* Congestive heart failure class ≥2 according to New York Heart Association criteria (NYHA)\n* Active coronary heart disease (myocardial infarction within 6 months of the study)\n* Severe pulmonary hypertension suspected on echocardiogram (systolic pulmonary arterial pressure \\[PAPs\\]\\> 35 mmHg) and confirmed with right cardiac catheterization (PAPs\\> 45mmHg)\n* Chronic renal failure (creatinine\\> 3 mg\u002Fdl)\n* Performance status ≥2 according to the Eastern Cooperative Oncology Group scale (ECOG)\n* History of grade III-IV hepatic encephalopathy or West Haven grade I-II hepatic encephalopathy episodes within the last 3 months\n* Uncontrolled systemic sepsis\n* Presence of Hepatocellular carcinoma\n* Complete portal vein thrombosis\n* Active bleeding from gastroesophageal varices. Patients with adequately treated gastroesophageal varices can be included in the study (banding ligation, sclerotherapy)\n* Diagnosis of extra hepatic neoplasia\n* Transplant recipients\n* Patients unable or unwilling to comply with the protocol requirements\n* Pregnant or lactating women\n* Patients unable to autonomously express their consent (incapable patients)\n* any other laboratory condition or result that in the opinion of the Principal Investigator, preclude the subject's participation in the study","80 Years",{"count":57,"type":20},72,"INTERVENTIONAL",[60],"PHASE3","The hypothesis is that in patients with cirrhosis and refractory ascites candidate to TIPS, and sarcopenia (identified by a PMA ≤16 cm² at the level of L3), who are at high-risk of 6-month mortality after TIPS placement, a post-TIPS 12 weeks nutritional intervention is associated with improved post-TIPS prognosis.\n\nThe primary objective is to evaluate the effect of a post-TIPS 12 weeks nutritional intervention on liver transplant-free six-month survival in sarcopenic candidates to TIPS for refractory ascites in cirrhosis.",[63,64,26],"Liver Cirrhosis","Refractory Ascites in Patients with Cirrhosis",[66,67,68,69,70,71],"nutritional treatment","sarcopenia","liver cirrhosis","refractory ascites","transjugular intrahepatic portosystemic shunt placement","TIPS","2025-02-07",{"date":74,"type":39},"2025-02-11",{"date":76,"type":39},"2022-10-13",{"date":78,"type":20},"2025-12",{"name":80,"class":81},"The Mediterranean Institute for Transplantation and Advanced Specialized Therapies","OTHER"]